180 related articles for article (PubMed ID: 16436719)
1. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.
Gu Z; Allard B; de Muys JM; Lippens J; Rando RF; Nguyen-Ba N; Ren C; McKenna P; Taylor DL; Bethell RC
Antimicrob Agents Chemother; 2006 Feb; 50(2):625-31. PubMed ID: 16436719
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs.
Bethell RC; Lie YS; Parkin NT
Antivir Chem Chemother; 2005; 16(5):295-302. PubMed ID: 16245645
[TBL] [Abstract][Full Text] [Related]
3. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
McColl DJ; Chappey C; Parkin NT; Miller MD
Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
[TBL] [Abstract][Full Text] [Related]
4. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
6. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
Ait-Khaled M; Rakik A; Griffin P; Cutrell A; Fischl MA; Clumeck N; Greenberg SB; Rubio R; Peters BS; Pulido F; Gould J; Pearce G; Spreen W; Tisdale M; Lafon S;
Antivir Ther; 2002 Mar; 7(1):43-51. PubMed ID: 12008787
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
8. Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells.
de Baar MP; de Rooij ER; Smolders KG; van Schijndel HB; Timmermans EC; Bethell R
Antiviral Res; 2007 Oct; 76(1):68-74. PubMed ID: 17628710
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.
Venhoff N; Setzer B; Melkaoui K; Walker UA
Antivir Ther; 2007; 12(7):1075-85. PubMed ID: 18018766
[TBL] [Abstract][Full Text] [Related]
10. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.
Cahn P; Wainberg MA
J Antimicrob Chemother; 2010 Feb; 65(2):213-7. PubMed ID: 20007333
[TBL] [Abstract][Full Text] [Related]
11. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
[TBL] [Abstract][Full Text] [Related]
12. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
[TBL] [Abstract][Full Text] [Related]
14. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.
Whitcomb JM; Parkin NT; Chappey C; Hellmann NS; Petropoulos CJ
J Infect Dis; 2003 Oct; 188(7):992-1000. PubMed ID: 14513419
[TBL] [Abstract][Full Text] [Related]
15. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
Margot NA; Waters JM; Miller MD
Antimicrob Agents Chemother; 2006 Dec; 50(12):4087-95. PubMed ID: 16982781
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD
Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055
[TBL] [Abstract][Full Text] [Related]
18. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
19. 4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.
Kodama EI; Kohgo S; Kitano K; Machida H; Gatanaga H; Shigeta S; Matsuoka M; Ohrui H; Mitsuya H
Antimicrob Agents Chemother; 2001 May; 45(5):1539-46. PubMed ID: 11302824
[TBL] [Abstract][Full Text] [Related]
20. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
